These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7742764

  • 21. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.
    Nagler A, Bishara A, Brautbar C, Barak V.
    Cytokines Cell Mol Ther; 1998 Sep; 4(3):161-7. PubMed ID: 9825841
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
    Schots R, Kaufman L, Van Riet I, Lacor P, Trullemans F, De Waele M, Van Camp B.
    Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
    [Abstract] [Full Text] [Related]

  • 25. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation.
    Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR, Ramsay NK, Kersey JH, Weisdorf DJ.
    Bone Marrow Transplant; 1994 Apr; 13(4):455-60. PubMed ID: 8019471
    [Abstract] [Full Text] [Related]

  • 26. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA.
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [Abstract] [Full Text] [Related]

  • 27. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J.
    Bone Marrow Transplant; 1998 Oct; 22(8):755-61. PubMed ID: 9827972
    [Abstract] [Full Text] [Related]

  • 28. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
    Zapatero A, Martín de Vidales C, Pinar B, Rodríguez F, Marín A, Cerezo L, Domínguez P, Pérez Torrubia A.
    Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M, Khojasteh HN, Ramzi M, Haghshenas M.
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [Abstract] [Full Text] [Related]

  • 31. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.
    Hempel L, Körholz D, Nussbaum P, Bönig H, Burdach S, Zintl F.
    Bone Marrow Transplant; 1997 Sep; 20(5):365-8. PubMed ID: 9339750
    [Abstract] [Full Text] [Related]

  • 32. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients.
    Humar A, St Louis P, Mazzulli T, McGeer A, Lipton J, Messner H, MacDonald KS.
    J Infect Dis; 1999 Feb; 179(2):484-8. PubMed ID: 9878035
    [Abstract] [Full Text] [Related]

  • 33. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet JP, Cordonnier C, Frassoni F.
    J Clin Oncol; 2004 Feb 01; 22(3):416-23. PubMed ID: 14691124
    [Abstract] [Full Text] [Related]

  • 34. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S.
    Haematologica; 1998 Jan 01; 83(1):48-55. PubMed ID: 9542323
    [Abstract] [Full Text] [Related]

  • 35. Correlation of low histidine rich glycoprotein plasma levels with the occurrence of acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Mauz-Körholz C, Körholz D, Burdach S.
    J Lab Clin Med; 1995 Aug 01; 126(2):144-50. PubMed ID: 7636387
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Aug 01; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
    MacMillan ML, Radloff GA, Kiffmeyer WR, DeFor TE, Weisdorf DJ, Davies SM.
    Transplantation; 2003 Dec 27; 76(12):1758-62. PubMed ID: 14688528
    [Abstract] [Full Text] [Related]

  • 40. [Significance of interleukin 10 for acute graft versus host disease in children and adolescents after allogenic bone marrow transplantation].
    Körholz D, Hempel L, Packeisen J, Kunst D, Zintl F, Burdach S.
    Klin Padiatr; 1996 Dec 27; 208(4):141-4. PubMed ID: 8926680
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.